Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $205.